WO2010016766A3 - Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène - Google Patents

Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène Download PDF

Info

Publication number
WO2010016766A3
WO2010016766A3 PCT/NL2009/050486 NL2009050486W WO2010016766A3 WO 2010016766 A3 WO2010016766 A3 WO 2010016766A3 NL 2009050486 W NL2009050486 W NL 2009050486W WO 2010016766 A3 WO2010016766 A3 WO 2010016766A3
Authority
WO
WIPO (PCT)
Prior art keywords
lgr6
antibodies
antibodies recognizing
endogenous human
lgr5
Prior art date
Application number
PCT/NL2009/050486
Other languages
English (en)
Other versions
WO2010016766A2 (fr
Inventor
Johannes Carolus Clevers
Nicholas Barker
Andrea Haegebarth
Marcus Lambertus Van De Wetering
Original Assignee
Koninklijke Nederlandse Akademie Van Wetenschappen
Hubrecht Laboratorium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2008/050543 external-priority patent/WO2009022907A2/fr
Application filed by Koninklijke Nederlandse Akademie Van Wetenschappen, Hubrecht Laboratorium filed Critical Koninklijke Nederlandse Akademie Van Wetenschappen
Publication of WO2010016766A2 publication Critical patent/WO2010016766A2/fr
Publication of WO2010016766A3 publication Critical patent/WO2010016766A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux anticorps qui se lient au récepteur couplé aux protéines G contenant une séquence répétée riche en leucine 5 (Lgr5) et/ou à Lgr6. En particulier, l'invention concerne des anticorps qui reconnaissent un Lgr5 et/ou un Lgr6 endogène. L'invention concerne également des procédés pour générer lesdits anticorps et les utilisations de tels anticorps.
PCT/NL2009/050486 2008-08-08 2009-08-07 Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène WO2010016766A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NLPCT/NL2008/050543 2008-08-08
PCT/NL2008/050543 WO2009022907A2 (fr) 2007-08-10 2008-08-08 Procédé d'identification, d'expansion et de retrait de cellules souches adultes et de cellules souches cancéreuses
EP09075065 2009-02-10
EP09075065.4 2009-02-10

Publications (2)

Publication Number Publication Date
WO2010016766A2 WO2010016766A2 (fr) 2010-02-11
WO2010016766A3 true WO2010016766A3 (fr) 2010-05-06

Family

ID=41066548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2009/050486 WO2010016766A2 (fr) 2008-08-08 2009-08-07 Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène

Country Status (1)

Country Link
WO (1) WO2010016766A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (fr) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Organoïde du foie, ses utilisations et son procédé de culture pour l'obtenir
KR101904224B1 (ko) 2009-02-03 2018-10-04 코닌클리즈케 네덜란드세 아카데미 반 베텐샤펜 상피 줄기 세포용 배양 배지 및 상기 줄기 세포를 포함하는 오르가노이드
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP4190149A1 (fr) 2009-12-25 2023-06-07 Chugai Seiyaku Kabushiki Kaisha Procédé de recherche et de criblage de cible d'agent anticancéreux à l'aide d'un modèle animal non humain ayant une lignée cellulaire cancéreuse établie nog transplantée
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
US9057096B2 (en) 2011-05-20 2015-06-16 Board Of Regents Of The University Of Texas System Regulation of Wnt/beta-catenin signaling
WO2013012747A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
EP2749641B1 (fr) * 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Séparation de cellules souches cancéreuses
JP2014530816A (ja) * 2011-10-14 2014-11-20 ノバルティスアーゲー Ｗｎｔ経路関連疾患のための抗体および方法
JP6291254B2 (ja) 2011-10-28 2018-03-14 中外製薬株式会社 癌幹細胞特異的分子
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
JP2014533247A (ja) * 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
WO2013067060A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
SG11201500233PA (en) 2012-07-13 2015-04-29 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
WO2014192974A1 (fr) * 2013-05-30 2014-12-04 株式会社オーダーメードメディカルリサーチ Réactif contenant des anticorps anti-lgr6 pour la détection et le diagnostic du cancer
EP3046940B1 (fr) 2013-09-17 2019-07-03 F.Hoffmann-La Roche Ag Procédés d'utilisation d'anticorps anti-lgr5
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
CA2949171A1 (fr) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Procede de culture ameliore pour organoides
CN106459202A (zh) 2014-06-11 2017-02-22 豪夫迈·罗氏有限公司 抗LgR5抗体及其用途
EP3191526B1 (fr) 2014-09-12 2023-02-22 The Board of Trustees of the Leland Stanford Junior University Molécules d'agonistes de la signalisation wnt
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
WO2016057629A1 (fr) * 2014-10-07 2016-04-14 Duke University Procédés et thérapeuthiques concernant la protéine r-spondine humaine et la protéine de récepteurs couplés aux protéines g contenant des motifs répétés riches en leucine
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN105274061A (zh) * 2015-10-26 2016-01-27 无锡傲锐东源生物科技有限公司 抗lgr5蛋白单克隆抗体杂交瘤细胞及其产生的抗lgr5单克隆抗体和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2017161414A1 (fr) 2016-03-22 2017-09-28 Bionomics Limited Administration d'un anticorps monoclonal anti-lgr5
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharma conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
US12006368B2 (en) 2017-12-19 2024-06-11 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
EP3732201A4 (fr) 2017-12-19 2022-04-20 Surrozen Operating, Inc. Molécules de substitution de wnt et leurs utilisations
WO2023166318A2 (fr) * 2022-03-03 2023-09-07 Cambridge Enterprise Limited Anticorps thérapeutiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074436A2 (fr) * 2003-02-19 2004-09-02 Incyte Corporation Procede d'utilisation d'un gpcr pour diagnostiquer et traiter le cancer du colon et du poumon
WO2005074980A1 (fr) * 2004-01-29 2005-08-18 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de gpr49
EP1602930A2 (fr) * 2003-08-22 2005-12-07 Hinzmann, Bernd, Dr. Utilisation de substances se liant à GPR49 pour le diagnostic et le traitement du cancer
WO2009005809A2 (fr) * 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074436A2 (fr) * 2003-02-19 2004-09-02 Incyte Corporation Procede d'utilisation d'un gpcr pour diagnostiquer et traiter le cancer du colon et du poumon
EP1602930A2 (fr) * 2003-08-22 2005-12-07 Hinzmann, Bernd, Dr. Utilisation de substances se liant à GPR49 pour le diagnostic et le traitement du cancer
WO2005074980A1 (fr) * 2004-01-29 2005-08-18 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de gpr49
WO2009005809A2 (fr) * 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Compositions et procédés de traitement et de diagnostic d'un cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARKER N ET AL: "Tracking Down the Stem Cells of the Intestine: Strategies to Identify Adult Stem Cells", GASTROENTEROLOGY 200712 US, vol. 133, no. 6, December 2007 (2007-12-01), pages 1755 - 1760, XP022421677, ISSN: 0016-5085 *
BARKER N, VAN ES JH, KUIPERS J, KUJALA P, VAN DEN BORN M, COZIJNSEN M, HAEGEBARTH A, KORVING J, BEGTHEL H, PETERS PJ, CLEVERS H.: "Identification of stem cells in small intestine and colon by marker gene Lgr5.", NATURE, vol. 449, 25 October 2007 (2007-10-25), pages 1003 - 1008, XP002457164 *
BECKER LAREN ET AL: "Immunostaining of Lgr5, an Intestinal Stem Cell Marker, in Normal and Premalignant Human Gastrointestinal Tissue", THESCIENTIFICWORLDJOURNAL, vol. 8, 2008, pages 1168 - 1176, XP002547818, ISSN: 1537-744X *
MCCLANAHAN T ET AL: "Identification of overexpression of orphan G Protein-Coupled Receptor GPR49 in human colon and ovarian primary tumors", CANCER BIOLOGY AND THERAPY 2006 UNITED STATES, vol. 5, no. 4, 2006, pages 419 - 426, XP002457160, ISSN: 1538-4047 1555-8576 *
MORITA H ET AL: "Neonatal lethality of LGR5 null mice is associated with ankyloglossia and gastrointestinal distension", MOLECULAR AND CELLULAR BIOLOGY 2004 UNITED STATES, vol. 24, no. 22, 2004, pages 9736 - 9743, XP002457162, ISSN: 0270-7306 *
MORRIS REBECCA J ET AL: "Capturing and profiling adult hair follicle stem cells", NATURE BIOTECHNOLOGY, vol. 22, no. 4, April 2004 (2004-04-01), pages 411 - 417, XP002457159, ISSN: 1087-0156 *
VAN DER FLIER L G ET AL: "The Intestinal Wnt/TCF Signature", GASTROENTEROLOGY 2007 UNITED STATES, vol. 132, no. 2, February 2007 (2007-02-01), pages 628 - 632, XP002457161, ISSN: 0016-5085 *
YAMAMOTO Y ET AL: "OVEREXPRESSION OF ORPHAN G-PROTEIN-COUPLED RECEPTOR, GPR49, IN HUMAN HEPATOCELLULAR CARCINOMAS WITH BETA-CATENIN MUTATIONS", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 37, no. 3, March 2003 (2003-03-01), pages 528 - 533, XP008041122, ISSN: 0270-9139 *
YEN TZUNG-HAI ET AL: "The gastrointestinal tract stem cell niche.", STEM CELL REVIEWS 2006, vol. 2, no. 3, 2006, pages 203 - 212, XP002457163, ISSN: 1550-8943 *

Also Published As

Publication number Publication date
WO2010016766A2 (fr) 2010-02-11

Similar Documents

Publication Publication Date Title
WO2010016766A3 (fr) Anticorps reconnaissant un lgr5 et/ou un lgr6 humain endogène
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2011047087A3 (fr) Détection de protéine par l'intermédiaire de nanorapporteurs
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2009091826A3 (fr) Compositions et procédés associés à un récepteur d'antigène chimérique spécifique du cd19 humain (h-car)
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2008060705A3 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
TN2010000213A1 (en) Wise binding antibodies and epitopes
MY171841A (en) Antibody formulation
WO2010142952A3 (fr) Anticorps
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
WO2007076070A3 (fr) Modulateurs de recepteurs muscariniques
WO2010037041A3 (fr) Agents se liant aux récepteurs frizzled et leurs utilisations
WO2007106721A3 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l'obesite
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
WO2010002478A3 (fr) Glycopeptide et son utilisation
WO2008112192A3 (fr) Anticorps epha3 utilises dans le traitement des tumeurs solides
WO2007131219A3 (fr) Antagonistes /agonistes inverses des récepteurs cannabinoïdes utilisés pour traiter des troubles du métabolisme, notamment l'obésité et le diabète
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09788269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09788269

Country of ref document: EP

Kind code of ref document: A2